Related Experiment Video
Updated: May 5, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
8.4K
Lipid Nanoparticles with Stiripentol and Cannabidiol Oil: From Rational Optimization to Preclinical Characterization
Sebastián Scioli-Montoto1,2, Martin Lobos1, Mauricio Melis1
1Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata 1900, Argentina.
Pharmaceutics
|May 4, 2026
Summary
A new nanostructured lipid carrier formulation effectively combines stiripentol (STP) and cannabidiol (CBD) for treating Dravet Syndrome (DS). This novel approach improves drug delivery and patient compliance in pediatric epilepsy management.
Area of Science:
- Pharmaceutical Nanotechnology
- Drug Delivery Systems
- Epilepsy Therapeutics
Background:
- Dravet Syndrome (DS) is a severe epilepsy requiring polytherapy with antiseizure medications (ASMs).
- Co-administration of stiripentol (STP) and cannabidiol (CBD) shows efficacy but faces formulation challenges (low solubility, poor bioavailability, poor palatability).
- High dosages and oily formulations of current treatments hinder pediatric patient compliance.
Purpose of the Study:
- To develop and characterize a novel nanostructured lipid carrier (NLC) formulation for co-delivering STP and CBD.
- To address formulation challenges and improve therapeutic outcomes for Dravet Syndrome patients.
- To enhance drug bioavailability and patient adherence in pediatric populations.
Main Methods:
- Development of aqueous NLCs encapsulating STP and CBD.
- Optimization using Response Surface Methodology (RSM).
- Comprehensive in vitro and in vivo characterization, including physicochemical analysis and pharmacokinetic profiling.
Main Results:
- Optimized NLCs exhibited favorable physicochemical properties (175.3 nm particle size, 0.232 PDI, -8.35 mV zeta potential) with >99% encapsulation efficiency.
- Nanoparticles were spherical, stable, and ensured molecular dispersion of STP and CBD.
- Sustained drug release profiles and comparable or superior oral pharmacokinetics to commercial products were observed.
Conclusions:
- The novel NLC formulation offers a promising therapeutic strategy for Dravet Syndrome.
- It enables effective co-administration of STP and CBD, potentially improving bioavailability.
- This formulation may enhance treatment adherence in pediatric populations due to improved properties.
